Department of Cell and Molecular Biology, Karolinska Institutet, 171 77 Stockholm, Sweden.
Department of Surgery, Yale University School of Medicine, New Haven, CN 06510, USA.
Int J Mol Sci. 2022 Mar 23;23(7):3482. doi: 10.3390/ijms23073482.
The human heart has the least regenerative capabilities among tissues and organs, and heart disease continues to be a leading cause of mortality in the industrialized world with insufficient therapeutic options and poor prognosis. Therefore, developing new therapeutic strategies for heart regeneration is a major goal in modern cardiac biology and medicine. Recent advances in stem cell biology and biotechnologies such as human pluripotent stem cells (hPSCs) and cardiac tissue engineering hold great promise for opening novel paths to heart regeneration and repair for heart disease, although these areas are still in their infancy. In this review, we summarize and discuss the recent progress in cardiac tissue engineering strategies, highlighting stem cell engineering and cardiomyocyte maturation, development of novel functional biomaterials and biofabrication tools, and their therapeutic applications involving drug discovery, disease modeling, and regenerative medicine for heart disease.
人类心脏的组织和器官再生能力最低,心脏病仍然是工业化世界的主要死亡原因,治疗选择有限,预后不佳。因此,开发心脏再生的新治疗策略是现代心脏生物学和医学的主要目标。干细胞生物学和生物技术的最新进展,如人类多能干细胞(hPSCs)和心脏组织工程,为心脏病的心脏再生和修复开辟了新的途径,尽管这些领域仍处于起步阶段。在这篇综述中,我们总结和讨论了心脏组织工程策略的最新进展,重点介绍了干细胞工程和心肌细胞成熟、新型功能生物材料和生物制造工具的发展,以及它们在药物发现、疾病建模和心脏病再生医学等方面的治疗应用。